A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects
Status:
Completed
Trial end date:
2017-01-17
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetic bioequivalence of DMB-3113 and adalimumab and to confirm the
safety of the study drug in healthy Japanese adult male subjects